A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors

Cancer ◽

10.1002/cncr.27459 ◽

2012 ◽

Vol 118 (19) ◽

pp. 4795-4800 ◽

Author(s):

Diane L. Reidy-Lagunes ◽

Efsevia Vakiani ◽

Michal F. Segal ◽

Ellen M. Hollywood ◽

Laura H. Tang ◽

...

Keyword(s):

Growth Factor ◽

Neuroendocrine Tumors ◽

Insulin Like Growth Factor ◽

Phase 2 ◽

Phase 2 Study ◽

Well Differentiated ◽

Receptor Inhibitor

Download Full-text

A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4163 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4163-4163 ◽

Author(s):

D. L. Reidy ◽

E. Hollywood ◽

M. Segal ◽

L. Saltz

Keyword(s):

Clinical Trial ◽

Growth Factor ◽

Neuroendocrine Tumors ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Insulin Like Growth Factor ◽

Well Differentiated ◽

Receptor Inhibitor

Download Full-text

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of Oncology ◽

10.1093/annonc/mdx078 ◽

2017 ◽

Vol 28 (6) ◽

pp. 1309-1315 ◽

Author(s):

M.H. Kulke ◽

P. Ruszniewski ◽

E. Van Cutsem ◽

C. Lombard-Bohas ◽

J.W. Valle ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Phase 2 ◽

Pancreatic Neuroendocrine Tumors ◽

Phase 2 Study ◽

Open Label Phase ◽

Well Differentiated

Download Full-text

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

Investigational New Drugs ◽

10.1007/s10637-018-0574-0 ◽

2018 ◽

Vol 36 (3) ◽

pp. 451-457 ◽

Author(s):

Pedro Barata ◽

Matthew Cooney ◽

Allison Tyler ◽

John Wright ◽

Robert Dreicer ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Insulin Like Growth Factor ◽

Phase 2 ◽

Phase 2 Study ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant

Download Full-text

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

Annals of Oncology ◽

10.1093/annonc/mdz219 ◽

2019 ◽

Vol 30 (11) ◽

pp. 1846

Author(s):

M.H. Kulke ◽

P. Ruszniewski ◽

E. Van Cutsem ◽

C. Lombard-Bohas ◽

J.W. Valle ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Phase 2 ◽

Pancreatic Neuroendocrine Tumors ◽

Phase 2 Study ◽

Open Label Phase ◽

Well Differentiated

Download Full-text

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

Cancer Research ◽

10.1158/0008-5472.can-08-0835 ◽

2008 ◽

Vol 69 (1) ◽

pp. 161-170 ◽

Author(s):

Fei Huang ◽

Ann Greer ◽

Warren Hurlburt ◽

Xia Han ◽

Rameh Hafezi ◽

...

Keyword(s):

Growth Factor ◽

Differential Sensitivity ◽

Insulin Like Growth Factor ◽

Receptor Inhibitor

Download Full-text

Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study

Supportive Care in Cancer ◽

10.1007/s00520-018-4600-8 ◽

2019 ◽

Vol 27 (8) ◽

pp. 3027-3033 ◽

Author(s):

Einat Shacham Shmueli ◽

Ravit Geva ◽

Nirit Yarom ◽

Ayala Hubert ◽

Rita Keynan ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Clinical Study ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Skin Toxicity ◽

Phase 2 ◽

Double Blind ◽

Epidermal Growth ◽

Receptor Inhibitor

Download Full-text

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells

British Journal of Haematology ◽

10.1111/j.1365-2141.2008.07049.x ◽

2008 ◽

Vol 141 (4) ◽

pp. 470-482 ◽

Author(s):

Patricia Maiso ◽

Enrique M. Ocio ◽

Mercedes Garayoa ◽

Juan C. Montero ◽

Francesco Hofmann ◽

...

Keyword(s):

Multiple Myeloma ◽

Growth Factor ◽

Cell Cycle Arrest ◽

Insulin Like Growth Factor ◽

Myeloma Cells ◽

Factor I ◽

Cycle Arrest ◽

Growth Factor I ◽

Receptor Inhibitor

Download Full-text

GSK1838705A, an insulin-like growth factor-1 receptor/insulin receptor inhibitor, induces apoptosis and reduces viability of docetaxel-resistant prostate cancer cells both in vitro and in vivo

OncoTargets and Therapy ◽

10.2147/ott.s79105 ◽

2015 ◽

pp. 753 ◽

Author(s):

Chaozhao Liang ◽

Fayou Zhou ◽

Xianguo Chen ◽

Song Fan ◽

Sheng Tai ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Insulin Receptor ◽

Cancer Cells ◽

Insulin Like Growth Factor ◽

Prostate Cancer Cells ◽

Receptor Inhibitor

Download Full-text

Abstract 1276: A novel targeted oral insulin-like growth factor 1 (IGF-1) receptor inhibitor and its implications for patients with squamous cell lung carcinoma

10.1158/1538-7445.am2011-1276 ◽

2011 ◽

Author(s):

Simon Ekman ◽

Johan Harmenberg ◽

Åsa J. Hedlund ◽

Stefan Bergstrom ◽

Jan Erik Frödin ◽

...

Keyword(s):

Growth Factor ◽

Squamous Cell ◽

Lung Carcinoma ◽

Oral Insulin ◽

Insulin Like Growth Factor ◽

Squamous Cell Lung Carcinoma ◽

Cell Lung Carcinoma ◽

Receptor Inhibitor

Download Full-text

Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2)

10.1158/1538-7445.sabcs19-ot2-07-01 ◽

2020 ◽

Author(s):

Nick C. Turner ◽

Ian E. Krop ◽

Aditya Bardia ◽

Senthil Damodaran ◽

Miguel Martin ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor Receptor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Fibroblast Growth ◽

Breast Cancers ◽

Phase 2 ◽

Download Full-text